US Patent 12005061 Ophthalmic formulations of methotrexate
Patent 12005061 was granted and assigned to Aldeyra Therapeutics on June, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 12 Jun, 2024
Golden AI
Edits made to:
Infobox (+20 properties)
Article (+286 characters)
US Patent 12005061 Ophthalmic formulations of methotrexate
Article
Patent abstract
The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Dean Eliott0
Pramod Sarpotdar0
Stephen Gitu Machatha0
Tomasz Stryjewski0
Date of Patent
June 11, 2024
0Patent Application Number
179324530
Date Filed
September 15, 2022
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 12005061 Ophthalmic formulations of methotrexate
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
